Skip to main content

Table 4 Sensititvity analysis: mean costs/ cost differences depending on management of local relapse, given in € (2015)

From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neck

  IMRT IMRT + C12 difference
mean total costs (€)
re-RT always as IMRT
  mean unadjusted 15,078.- 29,636.- 14,558.-
  mean adjusted (3 monthly intervals) 15,204.- 31,859.- 16,655.-
  mean adjusted annually 12,066.- 30,108.- 18,042.-
  mean adjusted, 3.5% discount 11,635.- 28,558.- 16,923.-
  mean adjusted 3.0% discount 11,694.- 28,758.- 17,065.-
mean total costs (€)
re-RT always as C12
  mean unadjusted 24,570.- 36,554.- 11,984.-
  mean adjusted (3 monthly intervals) 25,058.- 41,745.- 16,687.-
  mean adjusted annually 18,707.- 39,272.- 20,565.-
  mean adjusted, 3.5% discount 17,810.- 36,050.- 18,240.-
  mean adjusted 3.0% discount 17,931.- 36,459.- 18,528.-